DK1776460T3 - Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet - Google Patents

Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet

Info

Publication number
DK1776460T3
DK1776460T3 DK05768791T DK05768791T DK1776460T3 DK 1776460 T3 DK1776460 T3 DK 1776460T3 DK 05768791 T DK05768791 T DK 05768791T DK 05768791 T DK05768791 T DK 05768791T DK 1776460 T3 DK1776460 T3 DK 1776460T3
Authority
DK
Denmark
Prior art keywords
altering
gene expression
modulating gene
cpg content
relates
Prior art date
Application number
DK05768791T
Other languages
English (en)
Inventor
Frank Notka
Marcus Graf
Doris Leikam
Ralf Wagner
David Raab
Original Assignee
Geneart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35839637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1776460(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102004037611A external-priority patent/DE102004037611B4/de
Priority claimed from DE200410037652 external-priority patent/DE102004037652B4/de
Application filed by Geneart Ag filed Critical Geneart Ag
Application granted granted Critical
Publication of DK1776460T3 publication Critical patent/DK1776460T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Control Of Electric Motors In General (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK05768791T 2004-08-03 2005-08-03 Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet DK1776460T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004037611A DE102004037611B4 (de) 2004-08-03 2004-08-03 Induzierbare Genexpression
DE200410037652 DE102004037652B4 (de) 2004-08-03 2004-08-03 Verfahren zur Modulation der Genexpression durch Änderung des CpG Gehalts
PCT/EP2005/008423 WO2006015789A2 (de) 2004-08-03 2005-08-03 Verfahren zur modulation der genexpression durch änderung des cpg gehalts

Publications (1)

Publication Number Publication Date
DK1776460T3 true DK1776460T3 (da) 2010-04-12

Family

ID=35839637

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05768791T DK1776460T3 (da) 2004-08-03 2005-08-03 Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet

Country Status (14)

Country Link
US (4) US8859275B2 (da)
EP (1) EP1776460B8 (da)
JP (1) JP4550115B2 (da)
KR (1) KR101222628B1 (da)
AT (1) ATE453716T1 (da)
AU (1) AU2005270430B2 (da)
BR (1) BRPI0513081A (da)
CA (1) CA2575490A1 (da)
DE (1) DE502005008794D1 (da)
DK (1) DK1776460T3 (da)
HK (1) HK1100089A1 (da)
IL (1) IL180786A (da)
MX (1) MX2007001292A (da)
WO (1) WO2006015789A2 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE502005008794D1 (de) * 2004-08-03 2010-02-11 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
WO2008069663A1 (en) 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
EP2019134A1 (en) * 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
AU2008279883B2 (en) 2007-07-26 2013-12-05 Uniqure Ip B.V. Baculoviral vectors comprising repeated coding sequences with differential codon biases
WO2010087709A1 (en) 2009-01-30 2010-08-05 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Alanine-glyoxylate aminotransferase therapeutics
WO2011100369A2 (en) * 2010-02-09 2011-08-18 The Trustees Of Columbia University In The City Of New York Methods for altering polypeptide expression and solubility
EP2646795B1 (en) 2010-11-29 2019-02-20 Dako Denmark A/S Methods for analyzing images of specimens processed by a programmable quantitative assay
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP2751729B1 (en) 2011-09-01 2020-10-21 Genome Compiler Corporation System for polynucleotide construct design, visualization and transactions to manufacture the same
WO2014153188A2 (en) 2013-03-14 2014-09-25 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
CN107058059B (zh) 2011-09-26 2020-08-07 基因技术股份公司 高效的小体积核酸合成
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
CN105637097A (zh) 2013-08-05 2016-06-01 特韦斯特生物科学公司 从头合成的基因文库
EP3461498A1 (en) * 2013-08-21 2019-04-03 CureVac AG Rabies vaccine
EP3574916A1 (en) * 2013-08-21 2019-12-04 CureVac AG Composition and vaccine for treating lung cancer
MX369154B (es) * 2013-08-21 2019-10-30 Curevac Ag Composición y vacuna para tratar cáncer de pulmón.
EP3586871A3 (en) * 2013-08-21 2020-03-11 CureVac AG Respiratory syncytial virus (rsv) vaccine
RU2712743C2 (ru) 2013-08-21 2020-01-30 Куревак Аг Вакцина против бешенства
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
KR20160043103A (ko) * 2013-08-21 2016-04-20 큐어백 아게 전립선암 치료를 위한 조성물 및 백신
US20170362627A1 (en) 2014-11-10 2017-12-21 Modernatx, Inc. Multiparametric nucleic acid optimization
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP3557262B1 (en) 2014-12-09 2022-08-10 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
CN107873055B (zh) 2015-05-29 2021-09-17 库瑞瓦格房地产有限公司 包括至少一个切向流过滤步骤的产生和纯化rna的方法
US10844373B2 (en) 2015-09-18 2020-11-24 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN108698012A (zh) 2015-09-22 2018-10-23 特韦斯特生物科学公司 用于核酸合成的柔性基底
CN115920796A (zh) 2015-12-01 2023-04-07 特韦斯特生物科学公司 功能化表面及其制备
EP3500672A4 (en) 2016-08-22 2020-05-20 Twist Bioscience Corporation NOVO SYNTHESIZED NUCLEIC ACID BANKS
KR102217487B1 (ko) 2016-09-21 2021-02-23 트위스트 바이오사이언스 코포레이션 핵산 기반 데이터 저장
WO2018087285A1 (en) 2016-11-10 2018-05-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Or10h1 antigen binding proteins and uses thereof
KR102514213B1 (ko) 2016-12-16 2023-03-27 트위스트 바이오사이언스 코포레이션 면역 시냅스의 변이체 라이브러리 및 그의 합성
SG11201907713WA (en) 2017-02-22 2019-09-27 Twist Bioscience Corp Nucleic acid based data storage
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
SG11201912057RA (en) 2017-06-12 2020-01-30 Twist Bioscience Corp Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2019051501A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation PROTEINS BINDING TO GPCR AND METHODS OF SYNTHESIS
JP7066840B2 (ja) 2017-10-20 2022-05-13 ツイスト バイオサイエンス コーポレーション ポリヌクレオチド合成のための加熱されたナノウェル
EP3735459A4 (en) 2018-01-04 2021-10-06 Twist Bioscience Corporation DNA-BASED DIGITAL INFORMATION STORAGE
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
EP3768858A1 (en) 2018-03-19 2021-01-27 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
KR20210013128A (ko) 2018-05-18 2021-02-03 트위스트 바이오사이언스 코포레이션 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN113766930A (zh) 2019-02-26 2021-12-07 特韦斯特生物科学公司 Glp1受体的变异核酸文库
CA3131691A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
US11332738B2 (en) 2019-06-21 2022-05-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP3989994A4 (en) * 2019-06-30 2023-08-09 John Fraser Wright RECOMBINANT AAV VECTORS WITH ALTERED IMMUNOGENICITY AND METHODS FOR THEIR PRODUCTION
US20220372138A1 (en) 2019-07-05 2022-11-24 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
EP3992205A1 (en) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Sars coronavirus-2 spike protein binding compounds
WO2022096536A1 (en) 2020-11-03 2022-05-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
EP4301402A1 (en) 2021-03-03 2024-01-10 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Bispecific antibodies enhancing cell mediated immune responses
CA3228365A1 (en) * 2021-08-11 2023-02-16 Solid Biosciences Inc. Treatment of muscular dystrophy
WO2024067780A1 (zh) * 2022-09-30 2024-04-04 南京金斯瑞生物科技有限公司 一种降低外源核酸免疫原性的密码子优化

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131267A1 (en) * 1995-06-07 2005-06-16 Talmadge Karen D. System and method for delivering a therapeutic agent for bone disease
EP1003531B1 (en) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
DE60022665T2 (de) * 1999-09-25 2006-06-22 Coley Pharmaceutical Gmbh Immunstimulierende nukeinsäuren
AU2001247445B2 (en) 2000-03-15 2006-09-21 Gaussia L.L.C. Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
EP1156112B1 (en) * 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
US6919204B2 (en) * 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
DE10053781B4 (de) 2000-10-30 2008-07-03 Geneart Ag Kernexportreportersystem
AU2002242872B2 (en) 2001-04-05 2006-12-14 Emd Millipore Corporation Improved gene expression
WO2002099105A2 (en) 2001-06-05 2002-12-12 Cellectis Methods for modifying the cpg content of polynucleotides
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ATE505476T1 (de) * 2002-07-16 2011-04-15 VGX Pharmaceuticals LLC Codon-optimierte synthetische plasmide
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
US8224574B2 (en) 2004-05-12 2012-07-17 Northrop Grumman Guidance And Electronics Company, Inc. System for multiple navigation components
DE502005008794D1 (de) 2004-08-03 2010-02-11 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
DE102007052344B3 (de) * 2007-11-02 2009-03-12 Geneart Ag Selektion kodierender Nukleinsäure-Konstrukte auf Abwesenheit von Frameshift-Mutationen
EP2970965A2 (en) * 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Dnai for the modulation of genes

Also Published As

Publication number Publication date
DE502005008794D1 (de) 2010-02-11
AU2005270430A1 (en) 2006-02-16
WO2006015789A2 (de) 2006-02-16
IL180786A0 (en) 2007-06-03
AU2005270430B2 (en) 2008-06-12
BRPI0513081A (pt) 2008-04-22
EP1776460B1 (de) 2009-12-30
US20150104832A1 (en) 2015-04-16
US20210155940A1 (en) 2021-05-27
US10273486B2 (en) 2019-04-30
WO2006015789A3 (de) 2006-06-01
US20190270999A1 (en) 2019-09-05
HK1100089A1 (en) 2007-09-07
IL180786A (en) 2013-08-29
EP1776460B8 (de) 2014-02-26
MX2007001292A (es) 2007-07-04
CA2575490A1 (en) 2006-02-16
EP1776460A2 (de) 2007-04-25
US20090324546A1 (en) 2009-12-31
JP4550115B2 (ja) 2010-09-22
ATE453716T1 (de) 2010-01-15
KR20070041605A (ko) 2007-04-18
KR101222628B1 (ko) 2013-01-16
JP2008507986A (ja) 2008-03-21
EP1776460B2 (de) 2013-12-25
US8859275B2 (en) 2014-10-14

Similar Documents

Publication Publication Date Title
DK1776460T3 (da) Fremgangsmåde til modulering af genekspression ved ændring af CpG-indholdet
DK1200580T3 (da) Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
ATE512228T1 (de) Induzierbare expressionssysteme
DE60332820D1 (de) Verfahren und mittel zur überwachung und modulation des gen-silencing
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
DE60132170D1 (de) Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden
WO2004005460A3 (en) Antisense modulation of hmg-coa reductase expression
EP1417351A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A)
MX2007006610A (es) Metodo para simplificar acidos nucleicos microbianos por modificacion quimica de citosinas.
DE60143901D1 (de) Antisense-modulation der clusterinexpression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
DK1117672T3 (da) Antisense-modulation af survivin-ekpression
BRPI0413969A (pt) modulação da transcrição ativada por -catenina/tcf
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2009135810A8 (en) Plants having enhanced yield-related traits and a method for making the same
WO2009016212A3 (en) Plants having enhanced yield-related traits and a method for making the same
EP1814597A4 (en) RNAI MODULATION OF BCR-ABL FUSION GENE AND APPLICATIONS THEREOF
WO2001083513A3 (en) Antisense modulation of inhibitor of dna binding-1 expression
WO2009100254A3 (en) Protein tyrosine phosphatase inhibitors
WO2007005840A3 (en) Compositions, kits and methods pertaining to stability modulation of pna oligomer/nucleic acid complexes
WO2004003201A3 (en) Antisense modulation of lrh1 expression
WO2003106645A3 (en) ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION